Significance of erythopoietin receptor antibody concentration in diabetes

Significance of erythopoietin receptor antibody concentration in diabetes - Erythopoietin receptor antibody in diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014475

Enrollment

100

Registered

2014-07-07

Start date

2014-07-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with diabetes 2)Patients with written informed concent to the study 3)Age over 20 and under 80 at the time of registration

Exclusion criteria

Exclusion criteria: 1)Patients with severe diabetic ketoacidosis or come within recent 6 month 2) Patents with severe infectious disease, peri-operation and severe trauma 3)Patients with pregnancy (possible pregnancy) or nursing. 4)Patients ineligible for some other medical reason by a physician

Design outcomes

Primary

Measure	Time frame
Plasma concentration of erythopoietin antobodies	—

Secondary

Measure	Time frame
Factors which may affect plasma concentration of erythopoietin antobodies 1)GAD antibodies 2)Thyrogloblin (Tg) antibodies 3)Peroxidase (Pox) antibodies 4) HbA1c, fasting and post-prandial blood glucose, immnunoreactive insulin (IRI) 5) Age 6) Anemia (Hb, Hct, RBC) 7) eGFR, urinal albumin/ Crea, clinical stage for nephropathy	—

Countries

Japan

Contacts

Public ContactYoshihisa Okamoto

Yokohama City University Medical Center Department of Endocrinology and Diabetes

yokamoto@yokohama-cu.ac.jp045-261-5656

Outcome results